IBOGAINE AND 5-MeO-DMT TREATMENT FOR SPECIAL OPERATIONS FORCES WITH OPERATOR SYNDROME: A PHENOMENOLOGICAL INVESTIGATION
References
Bartone, P. T., Roland, R. R., Picano, J. J., & Williams, T. J. (2008). Psychological hardiness predicts success in US Army Special Forces candidates.
International Journal of Selection and Assessment, 16(1), 78-81.
Blackburn, J. R., & Szumlinski, K. K. (1997). Ibogaine effects on sweet preference and amphetamine induced locomotion: implications for drug
addiction. Behavioural brain research, 89(1-2), 99-106.
Brett, D. (2021). Iboga: The root of all healing. Noble Sapien.
Cherian, K. N., Keynan, J. N., Anker, L., Faerman, A., Brown, R. E., Shamma, A., ... & Williams, N. R. (2024). Magnesium–ibogaine therapy in
veterans with traumatic brain injuries. Nature Medicine, 30(2), 373-381.
Cheyne, J. A., Rueffer, S. D., & Newby-Clark, I. R. (1999). Hypnagogic and hypnopompic
hallucinations during sleep paralysis: neurological and cultural construction of the night-mare. Consciousness and cognition, 8(3), 319-337.
Chang, Q., Hanania, T., Mash, D. C., & Maillet, E. L. (2015). Noribogaine reduces nicotine self-administration in rats. Journal of
Psychopharmacology, 29(6), 704-711.
Davis, A. K., Averill, L. A., Sepeda, N. D., Barsuglia, J. P., & Amoroso, T. (2020). Psychedelic
treatment for trauma-related psychological and cognitive impairment among US special operations forces veterans. Chronic Stress, 4, 2470547020939564.
Frueh, B. C., Madan, A., Fowler, J. C., Stomberg, S., Bradshaw, M., Kelly, K., ... & Beidel, D. C. (2020). “Operator syndrome”: A unique constellation of medical and behavioral health-care needs of military special operation forces. The International Journal of Psychiatry in Medicine, 55(4), 281-295.
Geoly, A., Coetzee, J. P., Azeez, A., Buchanan, D., Struckmann, W., Kim, B., Cherian, K.,
Keynan, N., Sridhar, M., Lissemore, J., Singal, P., Shanbour, A., Bandeira, I. D., Adamson, M. M., Saggar, M., Rolle, C., & Williams, N. R. (2024). Change in brain structure and age in veterans with TBIs following treatment with magnesium ibogaine. Abstract presented at the 30th Annual Meeting of the Organization for Human Brain Mapping. https://ww6.aievolution.com/hbm2401/index.cfm?do=abs.viewAbs&abs=4225
González, J., Cavelli, M., Castro-Zaballa, S., Mondino, A., Tort, A. B., Rubido, N., ... &
Torterolo, P. (2021). EEG gamma band alterations and REM-like traits underpin the acute effect of the atypical psychedelic ibogaine in the rat. ACS Pharmacology & Translational Science, 4(2), 517-525.
He, D. Y., McGough, N. N., Ravindranathan, A., Jeanblanc, J., Logrip, M. L., Phamluong, K., ... & Ron, D. (2005). Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. Journal of Neuroscience, 25(3), 619-628.
Hufford, D. J. (2005). Sleep paralysis as spiritual experience. Transcultural psychiatry, 42(1),
11-45.
Malcolm, B. J., Polanco, M., & Barsuglia, J. P. (2018). Changes in withdrawal and craving scores in participants undergoing opioid detoxification utilizing ibogaine. Journal of Psychoactive Drugs, 50(3), 256-265.
Marton, S., González, B., Rodríguez-Bottero, S., Miquel, E., Martínez-Palma, L., Pazos, M., ... & Carrera, I. (2019). Ibogaine administration modifies GDNF and BDNF expression in brain regions involved in mesocorticolimbic and nigral dopaminergic circuits. Frontiers in pharmacology, 10, 193.
Mash, D. C., Duque, L., & Page, B. (2018). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: clinical observations and treatment outcomes. Frontiers in pharmacology, 9, 345105.
Naranjo, C. The Healing Journey: New Approached to Healing. Pantheon Books, New York,
1974.
Minnich, J. E., Mann, S. L., Stock, M., Stolzenbach, K. A., Mortell, B. M., Soderstrom, K. E., ... & Kozlowski, D. A. (2010). Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects cortical neurons from dying following a traumatic brain injury. Restorative neurology and neuroscience, 28(3), 293-309.
Reckweg, J. T., Uthaug, M. V., Szabo, A., Davis, A. K., Lancelotta, R., Mason, N. L., &
Ramaekers, J. G. (2022). The clinical pharmacology and potential therapeutic applications of 5‐methoxy‐N, N‐dimethyltryptamine (5‐MeO‐DMT). Journal of Neurochemistry, 162(1), 128-146.
Schenberg, E. E. (2018). Psychedelic-assisted psychotherapy: A paradigm shift in psychiatric
research and development. Frontiers in pharmacology, 9, 733.
Schwelm, H. M., Zimmermann, N., Scholl, T., Penner, J., Autret, A., Auwärter, V., & Neukamm,
M. A. (2022). Qualitative and quantitative analysis of tryptamines in the poison of
Incilius alvarius (Amphibia: Bufonidae). Journal of analytical toxicology, 46(5),
540-548.
Steenkamp, M. M., Litz, B. T., & Marmar, C. R. (2020). First-line psychotherapies for military-
related PTSD. Jama, 323(7), 656-657.